INTRODUCTION
Montelukast is a leukotriene receptor antagonist (LTRA) with iupac name 2- [ 
EXPERIMENTAL Reagents and Chemicals
Montelukast API and doxofyllin API were obtained as gift sample from Chandra labs. Methanol, Sodium dihydrogen ortho phosphate Water, Potassium Dihydrogen ortho Phosphate, Dipotassium hydrogen ortho phosphate, Ammonium acetate, Tetra Hydro Furan, is used of HPLC grade and pur-chased Instrumentation Chromatographic separation was performed on a Shimadzu (LC 20 AT VP) HPLC with auto sampler and PDA Detector.variablewavelength programmable UV/VIS detector, HYPERSIL,ODS (C18 250x 4.6 ID) 5µm with10μl fixed loop. Chromatographic Conditions HYPERSIL, ODS (C18 250x4.6 ID) 5µm were the column used for separation. Mobile phase Containing a mixture of Ammonium acetate: Methanol in 1000 ml of water in the ratio (60:40) v/v was delivered at a flow rate of 1.0 ml/min with detection at 219nm. The mobile phase is filtered through a 0.45 nylon filter and sonicated for 20 min.
Method Development
Ammonium acetate, methanol and water in different proportions were tried and finally Ammonium acetate, methanol = 60:40 v/v was selected appropriate mobile phase which gave good resolution, retention time and acceptable system suitability parameters.
PROCEDURE

Preparation of standard solution
2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE was weighed in 100 ml of volumetric flask and dissolved in 10 ml of mobile phase and volume was made up to the mark with mobile phase. From above stock solution 2.5 µg/ml of MONTELUKAST and 100 µg/ml of DOXOFYLLINE were prepared by diluting 1ml to 10ml with mobile phase.
Procedure
Inject the samples to the RpHplc by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution and retention for performing valida tion parameters as per ICH guidelines
Linearity
Standard stock solutions of MONTELUKAST and DOXOFYLLINE (μ/ml) were prepared by dissolving 2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE in 100 ml of mobile phase. After that filtered the solution using 0.45-micron syringe filter and sonicated for 5 min and diluted to 100ml with mobile.
Procedure for Analysis of Tablets
For Standard sample Standard stock solutions of MONTELUKAST and DOXOFYLLINE (micro gram/ml) were prepared by dissolving 2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE insufficient mobile phase. After that the solution was filtered using 0.45-micron syringe filter and sonicated for 5min and diluted to 100 ml with mobile phase. Further dilutions were prepared in 5replicates of 2.5 μg/ml of MONTELUKAST and 100 μg/ml of DOXOFYLLINE were made by adding 1 ml of stock solution to 10 ml of mobile phase. For Tablet sample20 tablets (each tablet contains 10 mg of MONTELUKAST and 400 mg of DOXOFYLLINE) were weighed and taken into a mortar and crushed to fine powder and uniformly mixed. Tablet stock solutions of MONTELUKAST and DOXOFYLLINE (μg/ml) were prepared by dissolving weight equivalent to 2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE and dissolved in sufficient mobile phase. After that the solution was filtered using 0.45-micron syringe filter and sonicated for 5 min and diluted to 100ml with mobile phase.
METHOD VALIDATION
System Suitability
Standard solutions were prepared as per the test method and injected into the chromatographic system. The system suitability parameters like theoretical plates, resolution and asymmetric factor were evaluated. Procedure The standard solution was injected for five times and measured the area for all five injections in HP LC. The %RSD for the area of five replicate injections was found to be within the specified limits.
Specificity
There is no interference of mobile phase, solvent and placebo with the analyte peak and also the peak purity of analyte peak which indicate that the method is specific for the analysis of analytes in their dosage form.
Standard Sample
Standard stock solutions of MONTELUKAST and DOXOFYLLINE (microgram/ml) were prepared by dissolving 2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE dissolved in sufficient mobile phase. After that filtered the solution using 0.45-micron syringe filter and Sonicated for 5min and dilute to 100 ml with mobile phase. Further dilutions are prepared in 5 replicates of 2.5 μg/ml of MONTELUKAST and 100 μg/ml of DOXOFYLLINE was made by adding 1 ml of stock solution to 10 ml of mobile phase.
Tablet Sample
20 tablets (each tablet contains 10 mg of MONTELUKAST and 400 mg of DOXOFYLLINE) were weighed and taken into a mortar and crushed to fine powder and uniformly mixed. Tablet stock solutions of MONTELUKAST and DOXOFYLLINE (μg/ml) were prepared by dissolving weight equivalent to 2.5 mg of MONTELUKAST and 100 mg of DOXOFYLLINE and dissolved in sufficient mobile phase. After that filtered the solution using 0.45-micron syringe filter and Sonicated for 5 min and dilute to 100ml with mobile phase. Further dilutions are prepared in 5 replicates of 2.5 μg/ml of MONTELUKAST and 100 μg/ml of DOXOFYLLINE was made by adding 1 ml of stock solution to 10 ml of mobile phase.
Linearity
linearity responses in the range of1.5-3.5mg/ml of DOXOFYLLINE and 60-140mg/ml of MONTE LUKAS SODIUM . Linear regression data was given
Precision
The precision of the method was demonstrated by inter day and intraday studies. In the intraday studie s, solutions of standard and sample were repeated 3times in a day and percent relative standard deviati on (%RSD) was calculated. The intraday %RSD of Ritonavir and Atazanavir were foundto be 0.54 an d 0.8 respectively.In the interday variation studies, injections of standard and sample solutions were m ade on two days and % RSD was calculated. The interday % RSD for Ritonavir and Atazanavir were found to be 0.5 to 0.63 respectively. From the data obtained the developed RP-HPLC method was found to be precise.
Accuracy
Accuracy of the method was determined by Recovery studies. To the formulation (pre-analysed sample), the reference standards of the drugs were added at the level of 80%, 100%, 120%. The recovery studies were carried out three times and the percentage recovery and percentage mean recovery were calculated for drug is shown in table. To check the accuracy of the method, recovery studies were carried out by addition of standard drug solution to pre-analysed sample solution at three different levels 80%, 100%, 120%.
Limit of Detection and Limit of Quantification
The Limit of detection and quantification were calculated using standard deviation of the resp onse and slope of calibration curve. The LOD for this method was found to be 0.021 µg/ml & area 2.61 for MONTELUKAST and 1.54 µg/ml & area 104.45 for DOXOFYLLINE. The LOQ for this method was found to be 0.06 µg/ml & area 7.91 for MONTELUKAST and 4.68 µg/ml & area 316.51 for DOXOFYLLINE
Robustness
Robustness of the method was checked by making slight changes in chromatographic conditions like mobile phase ratio, pH of buffer, flow rate. It was observed that there were no marked changes in chromatograms, which demonstrated that the developed RP-HPLC method is robust.
RESULTS AND DISCUSSION
Chromatographic separation was achieved on a Hypersil C 18 column. The optimum wave length for the determination of Montelukast and Doxofylline was selected at 219nmonthe basis of Isosbestic point. Various trials were performed with different mobile phases in differentratios, Ammonium acetate: Methanol (60:40) was selected as good peak symmetry and resolution between the peaks was observed. The Retentiontime of Montelukast and Doxofylline were found to be 2.34 and 4.81 respectively. The retention times for both the drugs were considerably less compared to the retention time obtained for the drugs in the other mobile phase.
The different analytical performance parameters such as linearity, precision, accuracy, and specificity, LOD, LOQ were determined according to International Conferenceon Harmonization ICHQ2B guidelines. The calibration curve for Montelukast was obtained by plotting peak area versus the concentration over the range of 1.5-3.5 µg/mL and for Doxofylline over the concentration range of 60-140 µg/mL. From linearity the correlation coefficient R 2 value was found to be 0.999 for Montelukast and .998 for Doxofylline. The proposed HPLC method was also validated for system suitability, system precision and method precision. The %RSD in the peak area of drug was found to be less than2%.The number of theoretical plates was found to be not less than2000, which indicates efficient performance of the column. The limit of detection of Montelukast & Doxofylline 0.021 µg/ml & area 2.61 and 1.54 µg/ml & area 104.45 respectively. The limit of quantitation of Montelukast was found to be 0.06 µg/ml & area 7.91whereas for Doxofylline was 4.68 µg/ml & area 316.51.The percentage of recovery of Montelukast and Doxofylline was found to be 99.96% and 100.85% respectively. 
Specificity
Observation
It is observed from the above data, diluents or excipient peaks are not interfering with the MONTELUKAST and DOXOFYLLINE peaks. 
Limit of Detection
Observation
The LOD for this method was found to be 0. The slope S may be estimated from the calibration curve of the analyte.
The LOQ for this method was found to be 0.06 µg/ml & area 7.91 for MONTELUKAST and 4.68 µg/ml & area 316.51 for DOXOFYLLINE 6. Linearity and Range 
CONCLUSION
From the above experimental results and parameters it was concluded that, the developed method for the simultaneous estimation of MONTELUKAST&DOXOFYLLINE was found to be simple, precise, accurate and high resolution and shorter retention time makes this method more acceptable and cost effective and it can be effectively applied for routine analysis in research institutions, quality control
